Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This gene, ENSG00000248921, encodes a **pseudogene** corresponding to "ankyrin repeat, SAM and basic leucine zipper domain containing 1 (ASZ1)"[1]. Pseudogenes are nonfunctional DNA elements that resemble normal genes but have lost their protein-coding ability due to disabling mutations such as frameshifts, premature stop codons, or lack of regulatory elements[4][1][7]. Most pseudogenes, including this one, do not produce functional proteins and are not considered biologically active molecules or therapeutic targets[4][1]. They are classified as "junk DNA," though in rare cases, they may exert regulatory effects at the RNA level; however, there is no evidence suggesting any functional or disease-associated role for this pseudogene[4][7][1]. No alternative names (aliases), drug interactions, molecular functions, disease roles, or biomarker status are associated with this pseudogene. The entry is correct as per gene nomenclature, but it is not a molecular target as understood in therapeutic contexts, and its relevance is limited to genomics and pseudogene annotation[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ankyrin repeat, SAM and basic leucine zipper domain containing 1 pseudogene.